All In Biotech

Drug Trial Radar · NCT05338931

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: May 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Mar 15, 2022

Primary completion

Mar 15, 2030

Study completion Sep 15, 2030

Sponsor

Lead sponsor
AbClonIndustry
Sponsor type
Industry
First posted
Apr 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Conditions

  • B-cell Non Hodgkin Lymphoma

Interventions

  • AT101(Anti-CD19 Chimeric Antigen Receptor T cell)Drug

    Anti-CD19 Chimeric Antigen Receptor T cell

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerant dose (MTD) and Recommended Phase 2 Dose (RP2D)Time frame: 28 days
  2. Overall response rate (ORR) by Independent assessmentTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.